GLUE (Monte Rosa Therapeutics) FCF Margin %: -932.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GLUE Monte Rosa Therapeutics Inc GLUE
32 GF Score
Price $23.14
! 5 Warning Signs
View Full Analysis

What is Monte Rosa Therapeutics FCF Margin %?

Monte Rosa Therapeutics GLUE +5.33% 32 FCF Margin % is -932.00% as of Mar. 2026. GuruFocus rates GLUE with a GF Score™ of 32/100. The stock has 5 warning signs investors should review. Among 950 Biotechnology companies, Monte Rosa Therapeutics ranks better than 54.74% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Monte Rosa Therapeutics's Free Cash Flow for the three months ended in Mar. 2026 was $-39.24 Mil. Monte Rosa Therapeutics's Revenue for the three months ended in Mar. 2026 was $4.21 Mil. Therefore, Monte Rosa Therapeutics's FCF Margin % for the quarter that ended in Mar. 2026 was -932.00%.

As of today, Monte Rosa Therapeutics's current FCF Yield % is -1.01%.

The historical rank and industry rank for Monte Rosa Therapeutics's FCF Margin % or its related term are showing as below:

GLUE' s FCF Margin % Range Over the Past 10 Years
Min: -45.76   Med: 14.02   Max: 50.26
Current: -45.76

During the past 7 years, the highest FCF Margin % of Monte Rosa Therapeutics was 50.26%. The lowest was -45.76%. And the median was 14.02%.

GLUE's FCF Margin % is ranked better than
54.74% of 950 companies
in the Biotechnology industry
Industry Median: -81.28 vs GLUE: -45.76

Monte Rosa Therapeutics FCF Margin % Related Terms

Monte Rosa Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Monte Rosa Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Monte Rosa Therapeutics FCF Margin % Chart

Monte Rosa Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 50.26 -22.23

Monte Rosa Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -55.43 -157.00 781.46 -1,574.29 -932.00

GLUE vs SNDX, IOVA, TYRA: FCF Margin % Comparison

For the Biotechnology subindustry, Monte Rosa Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Monte Rosa Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Monte Rosa Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Monte Rosa Therapeutics's FCF Margin % falls into.


GLUE
32GF Score
Monte Rosa Therapeutics Inc GLUE
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Monte Rosa Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Monte Rosa Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-27.498/123.672
=-22.23 %

Monte Rosa Therapeutics's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-39.237/4.21
=-932.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -932.00% mean?
Monte Rosa Therapeutics (GLUE) has a FCF Margin % of -932.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Monte Rosa Therapeutics and its competitors. According to the industry distribution chart, Monte Rosa Therapeutics ranks #430 out of 950 companies in the Biotechnology industry, placing it in the top 45.3%.
Is Monte Rosa Therapeutics' FCF Margin % too high?
Monte Rosa Therapeutics' current FCF Margin % is -932.00%. Based on the distribution chart, Monte Rosa Therapeutics ranks #430 out of 950 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Monte Rosa Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Monte Rosa Therapeutics' FCF Margin % compare to SNDX and IOVA?
According to the Biotechnology industry distribution chart, Monte Rosa Therapeutics ranks #430 out of 950 companies for FCF Margin %. This puts Monte Rosa Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Monte Rosa Therapeutics and its competitors. Monte Rosa Therapeutics's current FCF Margin % is -932.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monte Rosa Therapeutics stock overvalued right now?
Monte Rosa Therapeutics (GLUE) has a current FCF Margin % of -932.00%. The current FCF Margin % is -932.00%. Monte Rosa Therapeutics' overall GF Score™ is 32/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Monte Rosa Therapeutics (GLUE), the current FCF Margin % is -932.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Monte Rosa Therapeutics Business Description

Address 321 Harrison Avenue, Suite 900, Boston, MA, USA, 02118
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
32GF Score

Get the complete analysis for GLUE

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$23.14
Price